ASMPT (00522.HK) -2.200 (-2.140%) Short selling $5.61M; Ratio 11.832% delivered a robust 4Q25 results that beat expectations, driven by booming AIDC demand and an one-time gain from the sale of its subsidiary AAMI, although an unfavorable product mix partially limited margin expansion, BOCI released a research report saying. The management's strong guidance for 1Q26, including orders, revenue and SEMI gross profit margin, all point to sustained demand chain in the AI-HBM and CoWoS-TCB through 2028.Related News M Stanley Selects 26 Chinese 'Best Business Models' Stocks (Table)Therefore, BOCI kept rating at Buy on ASMPT, and elevated its target price from $98 to $133.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)
AASTOCKS Financial News